Completed
Curdlan Sulfate: Single and Multi-Dose Treatment
What is being tested
Curdlan sulfate
Drug
Who is being recruted
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
From 18 to 60 Years
+16 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 1
Interventional
Summary
Principal SponsorAJI Pharma USA
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested. In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)
Principal SponsorAJI Pharma USA
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 60 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections
Criteria
4 inclusion criteria required to participate
No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or other malignancy.
No critical illness that would shorten life expectancy to < 16 weeks.
HIV seropositivity.
CD4 count < 500 cells/mm3.
12 exclusion criteria prevent from participating
Use of antiretroviral or other experimental therapies within 1 month prior to study entry.
Concurrent use of cytotoxic or immunosuppressive agents.
Concurrent radiotherapy.
History of heparin sensitivity.
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center